TCGA-GM-A2DK-01A-21R-A180-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 88
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.360
- COAGULATION+0.360
- ESTROGEN_RESPONSE_LATE+0.340
- MYOGENESIS+0.310
- ESTROGEN_RESPONSE_EARLY+0.290
- XENOBIOTIC_METABOLISM+0.290
- COMPLEMENT+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- BILE_ACID_METABOLISM+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- G2M_CHECKPOINT-0.470
- E2F_TARGETS-0.450
- MITOTIC_SPINDLE-0.400
- MYC_TARGETS_V1-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.320
- MTORC1_SIGNALING-0.220
- INTERFERON_ALPHA_RESPONSE-0.190
- NOTCH_SIGNALING-0.180
- PROTEIN_SECRETION-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 45b4921e-fce7-41f8-bb63-ed98343ceec8 | — | — | 0.864 |
| 2 | ERR2208943 | — | — | 0.860 |
| 3 | SAMN03290935 | — | — | 0.847 |
| 4 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.847 |
| 5 | TCGA-XF-A9SL-01A-11R-A39I-07 | — | — | 0.847 |
| 6 | MDT-AP-1254 | Med | Medulloblastoma | 0.845 |
| 7 | SNU761_LIVER | HCC | — | 0.843 |
| 8 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.841 |
| 9 | BS_E4F1D721 | Spinal Cord Ependymoma | — | 0.836 |
| 10 | SRR5088845 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |